Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4941735 | 0.76 | HSD11B1 (0.35) | HSD11B1HSD11B2SMN1; SMN2CYP3A4 | |
| SCHEMBL6175645 | 0.74 | HSD11B1 (0.38) | HSD11B1HSD11B2GAACYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4611963 | 0.73 | HSD11B1 (0.37) | HSD11B1HSD11B2GAACYP2C19ALDH1A1 | |
| SCHEMBL18918484 | 0.68 | SMN1; SMN2 (0.33) | HSD11B1HSD11B2GAACYP2C19ALDH1A1 | |
| SCHEMBL4934520 | 0.67 | TSHR (0.70) | ALDH1A1TSHR | |
| SCHEMBL59551 | 0.65 | — | — | |
| SCHEMBL232028 | 0.64 | NPSR1 (0.39) | HSD11B1HSD11B2GAACYP2C19ALDH1A1 | |
| SCHEMBL28582945 | 0.63 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| Water SCHEMBL9407658 | 0.63 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL309605 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | TACR2, TACR1, KIT | HSD11B1 3987/4885HSD11B2 3012/4885GAA 2781/4885 |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | KIT, TACR2, P2RX3 | HSD11B1 4116/4885HSD11B2 3397/4885GAA 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.